Will update share holder each TR122 Jul 2020 09:35
#DMTR Market cap /price £16mln/ 1.7p Shares in issue : 870mln Last results : May 2020 Revenues: maiden revenues £1mln Cash at last accounts £2.5mln Cash raised £2.1mln July 2020 Company aim : Create a shared data cloud where the platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made Clients include: Glaxo, Astrazenecia, Waters,BASF, Cancer Research Uk, and in July 2020 Novartis
Major shareholders (top 5) 1 IP group (CEO used to work there)28% 2 Richard Griffiths added 6.6mln 3 Scottish Enterprise Fund 7.76% 4 Prof Lee Cronin (scientific founder) 7.6% 5 Robert Quested 5.7%
Recent developments 2020 *Feb 2020 Chemify ( linked to Cronin lab) part of a grant funded project in: "Developing a chemical ontology is the first step towards the digitization of chemistry....to take one example, the UK pharmaceutical market is set to grow from $32B in 2016 to $43B by 2020, with around 5,000 UK companies in the area. In this proposal, we will interact with key companies (Deep Matter and GSK) " *Astra/Glaxo form part of the Uk government hub with bases in Oxford, Glasgow and others cities. * Astrazenica had signed an agreement in 2019 work with DMTR to " transform drug design using innovative digital technologies in combination with automation and AI. To get potential new medicines to patients faster" *Cancer Research at Beatson Glasgow to divert energy to tracking C19 and signed a deal with DMTR on 14th April for: the sharing of details of their experiments from anywhere and in real-time. A subsequent deployment in China is anticipated to take place later in 2020.
*30th April news that Astra are working on a vaccine( perhaps using DMTR technology) ," AstraZeneca has teamed up with the University of Oxford to develop and manufacture a vaccine for coronavirus, in a move that could allow for rapid vaccination"
*meanwhile DMTR scientific founder and 7.6% holder Prof. Cronin and the Cronin lab say they cracked the chemical code for the Remdesivir vaccine, in a tweet on 7th April he says "We have written chemical-code (XDL) to robotically make six antiviral drugs (Arbidol; Chloroquine; Favipiravir; Hydroxychloroquine; Remdesivir) *1st May : US authorises use of anti-viral drug Remdevisir. *May Japan,India and UK approve Remdevisir *June 4th 2020- signs collaboration with one of worlds leading companies in the chemicals sector. *July working with £200bln valued Novartis
1 fully funded 2 large bio tech contracts/clients due 3 growing industry adoption of their A.I/ deep learning drug discovery tech 4 records revenues last year 5 links with current major C19 vaccine players
The Directors believe that the DigitalGlassware™ platform offers a scalable, cash generative SaaS business model with the potential for high levels of recurring revenue. The intention is to continue to sell the platform as a SaaS user licence to industry laboratories, combined with a freemium model for selected other consumers. The Directors believe the opportunity for full site software and hardware deployments with large pharma companies should be greater than $100,000 per annum. The Group is actively progressing qualified and advancing sales opportunities.
InfoChem's lead software product, ICSynth™, is another key asset for the Group. This desktop machine learning based synthesis design tool reduces costs and identifies unique choices for chemical reactions. The Directors believe ICSynth™, along with other software solutions for chemistry, offer ongoing opportunities in a stable and growing market. The profitable model, and existing customer base including GSK, AstraZeneca, BASF, Thieme and SpringerNature, offers high margin products (with maintenance), royalties and expert consultancy services. Large pharma licence fees for ICSynth™ are currently between $50,000-$100,000 per annum and the Group has seen a rise in newly validated leads and paid trials since the acquisition of InfoChem.
Opportunity to accelerate growth
The Company has provided DigitalGlassware™ to a top 10 global pharmaceutical company, Novartis, and is finalising a collaboration agreement with them, which follows the Company's first DigitalGlassware™ collaboration with a large pharmaceutical company, AstraZeneca in December 2019